Join Growin Stock Community!

Lipocine inc.LPCN.US Overview

US StockHealthcare
(No presentation for LPCN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LPCN AI Insights

LPCN Overall Performance

LPCN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LPCN Recent Performance

-7.43%

Lipocine inc.

0.05%

Avg of Sector

-0.31%

S&P500

LPCN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LPCN Key Information

LPCN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LPCN Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Price of LPCN

LPCN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LPCN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.99
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.79
PB Ratio
3.94
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-126.66%
Revenue Growth (YoY)
-45.44%
Profit Growth (YoY)
-45.44%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.99
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.79
PB Ratio
3.94
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-126.66%
Revenue Growth (YoY)
-45.44%
Profit Growth (YoY)
-45.44%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is LPCN's latest earnings report released?

    The most recent financial report for Lipocine inc. (LPCN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LPCN's short-term business performance and financial health. For the latest updates on LPCN's earnings releases, visit this page regularly.

  • What is the operating profit of LPCN?

    According to the latest financial report, Lipocine inc. (LPCN) reported an Operating Profit of -3.36M with an Operating Margin of -2,933.51% this period, representing a decline of 27.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LPCN's revenue growth?

    In the latest financial report, Lipocine inc. (LPCN) announced revenue of 114.57K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does LPCN have?

    At the end of the period, Lipocine inc. (LPCN) held Total Cash and Cash Equivalents of 3.9M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LPCN go with three margins increasing?

    In the latest report, Lipocine inc. (LPCN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -2,933.51%%, and net margin of -2,781.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LPCN's profit trajectory and future growth potential.

  • Is LPCN's EPS continuing to grow?

    According to the past four quarterly reports, Lipocine inc. (LPCN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.59. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LPCN?

    Lipocine inc. (LPCN)'s Free Cash Flow (FCF) for the period is -2.99M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.